home / stock / trvn / trvn quote
Last: | $0.4126 |
---|---|
Change Percent: | -6.28% |
Open: | $0.4352 |
Close: | $0.4126 |
High: | $0.4352 |
Low: | $0.38 |
Volume: | 76,310 |
Last Trade Date Time: | 05/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.4126 | $0.4352 | $0.4126 | $0.4352 | $0.38 | 76,310 | 05-03-2024 |
$0.4095 | $0.391899 | $0.4095 | $0.41 | $0.38 | 77,020 | 05-02-2024 |
$0.3838 | $0.4 | $0.3838 | $0.4019 | $0.3838 | 38,257 | 05-01-2024 |
$0.4 | $0.42 | $0.4 | $0.42 | $0.38 | 36,165 | 04-30-2024 |
$0.4 | $0.39 | $0.4 | $0.4 | $0.3877 | 15,820 | 04-29-2024 |
$0.391 | $0.3978 | $0.391 | $0.409 | $0.3835 | 46,616 | 04-26-2024 |
$0.409 | $0.38 | $0.409 | $0.4199 | $0.37 | 114,900 | 04-25-2024 |
$0.381 | $0.3855 | $0.381 | $0.39 | $0.3639 | 61,305 | 04-24-2024 |
$0.388 | $0.3586 | $0.388 | $0.3999 | $0.3487 | 141,901 | 04-23-2024 |
$0.3702 | $0.3532 | $0.3702 | $0.3976 | $0.3232 | 434,814 | 04-22-2024 |
$0.352 | $0.347 | $0.352 | $0.3599 | $0.3227 | 170,496 | 04-19-2024 |
$0.366 | $0.4225 | $0.366 | $0.43 | $0.3625 | 1,241,939 | 04-18-2024 |
$0.402 | $0.38 | $0.402 | $0.41 | $0.3727 | 3,658,634 | 04-17-2024 |
$0.393 | $0.39 | $0.393 | $0.403 | $0.371 | 73,078 | 04-16-2024 |
$0.391854 | $0.379 | $0.391854 | $0.42 | $0.379 | 68,077 | 04-15-2024 |
$0.3814 | $0.419 | $0.3814 | $0.419 | $0.37 | 184,033 | 04-12-2024 |
$0.413 | $0.4098 | $0.413 | $0.42 | $0.4055 | 44,884 | 04-11-2024 |
$0.406 | $0.4054 | $0.406 | $0.42 | $0.4007 | 89,064 | 04-10-2024 |
$0.4003 | $0.41 | $0.4003 | $0.4249 | $0.4 | 81,019 | 04-09-2024 |
$0.4113 | $0.417 | $0.4113 | $0.423931 | $0.39 | 35,127 | 04-08-2024 |
News, Short Squeeze, Breakout and More Instantly...
2024-04-02 07:15:05 ET JMP Securities analyst issues MARKET OUTPERFORM recommendation for TRVN on April 2, 2024 05:40AM ET. The previous analyst recommendation was Market Outperform. TRVN was trading at $0.4 at issue of the analyst recommendation. Historical Analyst Re...
TRV045, novel S1P receptor modulator for chronic pain and epilepsy, advances toward important milestones in both non-clinical and clinical studies Company announces reduction of OLINVYK commercial support and review of alternatives for OLINVYK CHESTERBROOK, Pa., April 01, 2024 (GL...
CHESTERBROOK, Pa., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. ("Trevena" or the "Company") (NASDAQ:TRVN), a biopharmaceutical company focus...